v3.25.2
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
May 31, 2025
Dec. 31, 2024
May 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenue              
Revenue         $ 431,378 $ 1,295,889
Operating expenses              
Cost         (420,812) (1,215,824)
Research and development expenses $ (19,375) $ (2,038,923)   (2,195,161)   (5,198,329) (9,219,595)
General and administrative fees (187,422) (326,187)   (669,486)   (1,930,637) (5,220,405)
Legal and professional fees (418,881) (366,164)   (803,285)   (2,538,161) (2,888,140)
Other operating income (expenses) 222,912 (137,233)   (272,609)   (1,067,690) (261,038)
Total operating expenses (402,766) (2,868,507)   (3,940,541)   (11,155,629) (18,805,002)
Other (expense) income, net              
Loss on investments in marketable securities, net         (9,266) (134,134)
Unrealized gain from fair value change of the long-term investments, net         6,431,088 6,108,872
Impairment loss of long-term investment       (1,000,000)   (77,200) (520,821)
Interest expense, net (46,529) (68,462)   (146,924)   (121,145) 146,588
Loss on disposal of subsidiaries (4,271)   703  
Government subsidies       928,461   123,015 335,499
Sundry income 282,353   564   36,784 48,007
Total other (expenses) income, net (46,529) 209,620   (217,196)   6,383,276 5,984,011
Income taxes        
Net loss (449,295) (2,658,887)   (4,157,737)   (4,340,975) (11,525,102)
Less: net loss attributable to non-controlling interests (7,515) (15,091)   110,069   (1,516,328) (1,725,542)
Other comprehensive income (loss)              
Exchange differences on translation of foreign operations (258,322) 861   99,785   (44,430) 35,826
Other comprehensive (loss) income (258,322) 861   99,785   (44,430) 35,826
Comprehensive loss (707,617) (2,658,026)   (4,057,952)   (4,385,405) (11,489,276)
Comprehensive (loss) income attributable to non-controlling interests       (110,069)   1,516,328 1,725,542
Less: comprehensive loss attributable to non-controlling interests (7,515) (15,091)          
Comprehensive loss attributable to the shareholders of Aptorum Group Limited (700,102) (2,642,935)   (4,168,021)   (2,869,077) (9,763,734)
Operating costs and expenses              
Net (loss) income attributable to non-controlling interests 7,515 15,091   (110,069)   1,516,328 1,725,542
Net loss attributable to Aptorum Group Limited $ (441,780) $ (2,643,796)   $ (4,267,806)   $ (2,824,647) $ (9,799,560)
Net loss per share attributable to Aptorum Group Limited              
Net loss per share – basic (in Dollars per share) $ (0.06) $ (0.5)   $ (0.78) [1]   $ (0.62) [1] $ (2.75) [1]
Net loss per share – diluted (in Dollars per share) $ (0.06) $ (0.5)   $ (0.78)   $ (0.62) $ (2.75)
Weighted-average shares outstanding              
Weighted-average shares outstanding – basic (in Shares) 7,126,796 5,339,608   5,453,103 [1]   4,521,133 [1] 3,569,484 [1]
Weighted-average shares outstanding – diluted (in Shares) 7,126,796 5,339,608   5,453,103   4,521,133 3,569,484
DiamiR Biosciences Corp              
Revenue              
Revenue     $ 631,729   $ 1,319,531    
Other (expense) income, net              
Interest expense, net     82,046   48,599    
Total other (expenses) income, net     82,046   48,599    
Net loss before income taxes     (725,296)   (500,002)    
Income taxes     17,939   114,403    
Net loss     (743,235)   (614,405)    
Operating costs and expenses              
Research and development     650,591   1,156,860    
General and administrative     624,388   614,074    
Total operating costs and expenses     1,274,979   1,770,934    
Loss from operations     (643,250)   (451,403)    
Net loss attributable to Aptorum Group Limited     $ (743,235)   $ (614,405)    
Net loss per share attributable to Aptorum Group Limited              
Net loss per share – basic (in Dollars per share)     $ (0.17)   $ (0.14)    
Net loss per share – diluted (in Dollars per share)     $ (0.17)   $ (0.14)    
Weighted-average shares outstanding              
Weighted-average shares outstanding – basic (in Shares)     4,440,891   4,440,891    
Weighted-average shares outstanding – diluted (in Shares)     4,440,891   4,440,891    
Grant revenue | DiamiR Biosciences Corp              
Revenue              
Revenue     $ 531,729   $ 1,319,531    
Grant revenue | DiamiR Biosciences Corp              
Revenue              
Revenue     $ 100,000        
[1] All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED’s 1 for 10 reverse stock split, which was effective on January 23, 2023.